Search results
Results from the WOW.Com Content Network
Carboplatin, a cisplatin analogue, was developed by Bristol Myers Squibb and the Institute of Cancer Research in order to reduce the toxicity of cisplatin. [6] [20] It gained U.S. Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug ...
In September 2024, the FDA approved amivantamab-vmjw with carboplatin and pemetrexed for adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine ...
DailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care providers and the general public. The contents of DailyMed is provided and updated daily by the U.S. Food and Drug Administration (FDA). The FDA in turn collects this ...
The Food and Drug Administration approved the combination therapy of J&J's Rybrevant with carboplatin and pemetrexed for non-small cell lung cancer (NSCLC) patients with a type of mutation in EGFR ...
Cisplatin is a type of chemotherapy drug used alone or in combination with other drugs to treat several advanced forms of cancer, including bladder, ovarian and testicular cancer. The FDA last ...
The FDA is also exploring importing carboplatin, another chemotherapy drug in shortage, according to James McKinney, an agency spokesperson. However, McKinney told NBC News the agency could not ...
Each drug is listed once (at present), though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing. The agents in this list are often combined into chemotherapy agent for polychemotherapy (combination chemotherapy).
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product.